EUVIMEDEUVIMED entdecken
Leitlinie

A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction

Michael J Arnold iD, Lance Spacek iD, Kelvin N V Bush iD, Ashley Arana Waring, Jennifer Ballard-Hernandez iD, Darrick Beckman, Catherine Kelley, Sundar Natarajan, Brian E Neubauer iD, Edward M Phillips iD, Sophie Roberts, James Sall iD und 2 weitere

Annals of Internal Medicine · 2026

DOI: 10.7326/annals-26-01374 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von Michael J Arnold und 13 weiteren Autor:innen. Beteiligte Einrichtung: Uniformed Services University of the Health Sciences, Bethesda, Maryland, and Naval Undersea Medical Institute, Groton, Connecticut (M.J.A.). Hauptthemen laut MEDLINE: Cardiovascular Diseases, Hypolipidemic Agents, Dyslipidemias. Die Arbeit nennt 114 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DESCRIPTION: In December 2025, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) released a clinical practice guideline (CPG) update on lipid management for cardiovascular disease risk reduction in adults. This synopsis reviews the 2025 updates and describes the major recommendations. METHODS: The VA/DoD guideline development team updated the 2020 VA/DoD lipid management CPG with clinical stakeholders. The guideline panel developed 12 key questions, systematically evaluated the literature (English-language publications from 16 May 2019 to 15 January 2025), and developed 24 evidence-based recommendations. The recommendations were graded using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. RECOMMENDATIONS: This synopsis highlights key recommendations for lipid management that are new or differ from other guideline recommendations. This update recommends the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) calculator for risk estimation in primary prevention and removes a previous recommendation against routine lipid monitoring. Two new risk refinement strategies were added: Coronary artery calcium testing is suggested for patients with clinical uncertainty and intermediate-to-high calculated risk, and one-time lipoprotein(a) testing is recommended to identify patients with enhanced cardiovascular risk. For primary prevention, moderate-intensity statins remain the recommended treatment for those at higher risk and should be considered for those at intermediate risk. A new recommendation suggests moderate-intensity statins for adults living with HIV even when 10-year risk is low. This update shifts toward more intensive lipid-lowering therapy for secondary prevention. For very high-risk patients with atherosclerotic cardiovascular disease, the guideline now suggests combination therapy with high-intensity or maximally tolerated statins plus ezetimibe and/or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. For statin-intolerant patients, alternatives include bempedoic acid, ezetimibe, fibrates, or PCSK9 monoclonal antibody inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesHypolipidemic AgentsDyslipidemiasHumansUnited StatesHydroxymethylglutaryl-CoA Reductase InhibitorsUnited States Department of Veterans AffairsUnited States Department of DefenseRisk AssessmentHeart Disease Risk FactorsPrimary PreventionLipids

Substanzen

Hypolipidemic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsLipids

Autor:innen und Institutionen

  • Uniformed Services University of the Health Sciences, Bethesda, Maryland, and Naval Undersea Medical Institute, Groton, Connecticut (M.J.A.).
  • South Texas Veterans Health Care System, San Antonio, Texas (L.S.).
  • Uniformed Services University of the Health Sciences, Bethesda, Maryland; U.S. Air Force, Arlington, Virginia; and San Antonio Military Medical Center, San Antionio, Texas (K.N.V.B.).
  • Ralph H. Johnson VA Medical Center and Medical University of South Carolina, Charleston, South Carolina (A.A.W.).
  • Evidence-Based Practice Program, Quality and Patient Safety, Veterans Health Administration Central Office, Washington, DC (J.B.-H., J.S.).
  • Brooke Army Medical Center, San Antonio, Texas (D.B., B.E.N.).

ORCID-Profile: Michael J Arnold, Lance Spacek, Kelvin N V Bush, Jennifer Ballard-Hernandez, Brian E Neubauer, Edward M Phillips, James Sall, Paul Heidenreich

Zitieren

APA

Arnold, M. J., Spacek, L., Bush, K. N. V., Waring, A. A., Ballard-Hernandez, J., Beckman, D., Kelley, C., Natarajan, S., Neubauer, B. E., Phillips, E. M., Roberts, S., Sall, J., Walsh-Irwin, C., & Heidenreich, P. (2026). A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction. Annals of Internal Medicine. https://doi.org/10.7326/annals-26-01374

Vancouver

Arnold MJ, Spacek L, Bush KNV, Waring AA, Ballard-Hernandez J, Beckman D, et al. A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction. Annals of Internal Medicine. 2026. doi:10.7326/annals-26-01374

BibTeX
@article{Arnold2026,
  author = {Arnold, Michael J and Spacek, Lance and Bush, Kelvin N V and Waring, Ashley Arana and Ballard-Hernandez, Jennifer and Beckman, Darrick and Kelley, Catherine and Natarajan, Sundar and Neubauer, Brian E and Phillips, Edward M and Roberts, Sophie and Sall, James and Walsh-Irwin, Colleen and Heidenreich, Paul},
  title = {A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction},
  journal = {Annals of Internal Medicine},
  year = {2026},
  doi = {10.7326/annals-26-01374}
}
Kostenlos starten →